{"id":468536,"date":"2022-08-17T13:04:07","date_gmt":"2022-08-17T11:04:07","guid":{"rendered":"http:\/\/intervacc.se\/?p=468536"},"modified":"2022-08-17T13:04:08","modified_gmt":"2022-08-17T11:04:08","slug":"strangvac-a-vaccine-against-equine-strangles-is-now-available-for-sale-in-the-uk","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/strangvac-a-vaccine-against-equine-strangles-is-now-available-for-sale-in-the-uk\/","title":{"rendered":"Strangvac, a vaccine against equine strangles, is now available for sale in the UK"},"content":{"rendered":"
\n

Stockholm, August 17th 2022 – Intervacc AB (publ) announces today that Strangvac\u00ae<\/sup> is now available for sale in the UK.<\/p>\n<\/div>\n\n\n

This week Strangvac\u00ae<\/sup> has been launched in the UK and horse owners can now vaccinate their horses against the infectious equine disease Strangles. Dechra will be distributing the vaccine in the UK and in a number of European countries.<\/p>\n\n\n\n

\u201cStrangles is highly contagious and is one of the most common equine infectious diseases with an estimated 600 outbreaks each year in the UK alone. Feared by many horse owners due to the potential severity of the clinical signs and the speed at which it can spread through an affected farm, we are sure the new strangles vaccine will be a vital tool and a huge benefit to the equestrian industry as a whole\u201d<\/em> says Sara Barker, equine field support manager at Dechra Pharmaceuticals PLC.<\/p>\n\n\n\n

\u201cStrangvac\u00ae<\/sup> is approved for sale and marketing in the EU as well as the UK, Norway and Iceland, and has been launched in Sweden, Denmark and now also in the UK. The UK is expected to be one of the largest markets in Europe for a vaccine against this highly contagious infectious disease of horses\u201d<\/em> comments Andreas Andersson, CEO of Intervacc.<\/p>\n\n\n\n

For more information please contact:<\/strong><\/p>\n\n\n\n

Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com<\/p>\n\n\n\n

The information was submitted for publication, through the agency of the contact person set out above on August 17, 2022, 13.00 CET.<\/em><\/p>\n\n\n\n

About Intervacc<\/strong><\/p>\n\n\n\n

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company\u00b4s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8\u2013684 211 10 as Certified Adviser.<\/p>\n\n\n\n

About Dechra<\/strong><\/p>\n\n\n\n

Dechra is a global specialist veterinary pharmaceuticals and related products business. Dechra\u2019s expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH , LEI: 213800J4UVB5OWG8VX82<\/p>\n\n\n\n

About equine strangles<\/strong><\/p>\n\n\n\n

Equine strangles, caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. Streptococcus equi invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.<\/p>\n\n\n\n

Contact information for Certified Adviser<\/strong><\/p>\n\n\n\n

Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 \u2013 684 211 10<\/p>\n","protected":false},"excerpt":{"rendered":"

Stockholm, August 17th 2022 – Intervacc AB (publ) announces today that Strangvac\u00ae is now available for sale in the UK. […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[27],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/468536"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=468536"}],"version-history":[{"count":4,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/468536\/revisions"}],"predecessor-version":[{"id":468548,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/468536\/revisions\/468548"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=468536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=468536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=468536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}